Preventing CMV disease in cord blood recipients –Scientists at Fred Hutch developed a strategy for the prevention of cytomegalovirus (CMV) disease in patients receiving a cord blood transplant. The strategy, developed by Drs. Steve Pergam, Wendy Leisenring, Michael Boekch, Colleen Delaney and colleagues calls for ganciclovir (antiviral) to be administered before transplantation, high-dose acyclovir (antiviral) administered after transplantation, and then bi-weekly testing for the presence of the virus.
Reduced mortality from cytomegalovirus infections – A study examining mortality rates among hematopoietic cell transplant patients over a 10-year period found that the hazard of early cytomegalovirus disease (CMV) - a type of herpesvirus - decreased by 48 percent among all CMV patients. The study compared patients receiving transplants between the period of 2003-2007 as compared to 1993-1997. The reduction was attributed to improved detection methods and treatment for preventing CMV disease resulting from the reactivation of the virus.
The landmark study, published in 2010, was authored by a dozen Fred Hutch researchers who applied their individual expertise to examining improved survival rates among transplant recipients. Learn more >